These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25549489)

  • 1. [Modern diagnostic approaches to malignant hyperthermia susceptibility].
    Kazantseva AA; Lebedinskiĭ KM
    Anesteziol Reanimatol; 2014; 59(4):64-8. PubMed ID: 25549489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia.
    Bendahan D; Guis S; Monnier N; Kozak-Ribbens G; Lunardi J; Ghattas B; Mattei JP; Cozzone PJ
    Acta Anaesthesiol Scand; 2004 Sep; 48(8):1019-27. PubMed ID: 15315621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Similar susceptibility to halothane, caffeine and ryanodine in vitro reflects pharmacogenetic variability of malignant hyperthermia.
    Ginz HF; Girard T; Censier K; Urwyler A
    Eur J Anaesthesiol; 2004 Feb; 21(2):151-7. PubMed ID: 14977348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of chlorocresol vs caffeine on muscle contracture in malignant hyperthermia susceptible patients].
    Ben-Abraham R; Krivosic-Horber RM; Haudcoeur G; Perel A; Adnet PJ
    Harefuah; 1997 Jun; 132(12):839-41, 911. PubMed ID: 9264187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3,5-Di-t-butyl catechol is a potent human ryanodine receptor 1 activator, not suitable for the diagnosis of malignant hyperthermia susceptibility.
    Lacava C; Michalek-Sauberer A; Kraft B; Sgaragli G; Sipos E; Höller C; Kress HG; Fusi F; Weigl LG
    Pharmacol Res; 2012 Jul; 66(1):80-7. PubMed ID: 22480578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations.
    Fiege M; Wappler F; Weisshorn R; Ulrich Gerbershagen M; Steinfath M; Schulte Am Esch J
    Anesthesiology; 2002 Aug; 97(2):345-50. PubMed ID: 12151923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of discordance between genotype and phenotype in a malignant hyperthermia family.
    Fortunato G; Carsana A; Tinto N; Brancadoro V; Canfora G; Salvatore F
    Eur J Hum Genet; 1999; 7(4):415-20. PubMed ID: 10352931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biology of malignant hyperthermia: a disease of the calcium channels of the skeletal muscle].
    Monnier N; Lunardi J
    Ann Biol Clin (Paris); 2000; 58(2):147-56. PubMed ID: 10760701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
    Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
    Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant hyperthermia: update on susceptibility testing.
    Litman RS; Rosenberg H
    JAMA; 2005 Jun; 293(23):2918-24. PubMed ID: 15956637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of a positive malignant hyperthermia (MH) disposition without the in vitro contracture test in families carrying the RYR1 Arg614Cys mutation.
    Rueffert H; Olthoff D; Deutrich C; Froster UG
    Clin Genet; 2001 Aug; 60(2):117-24. PubMed ID: 11553045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro contracture testing for susceptibility to malignant hyperthermia: can halothane be replaced?
    Metterlein T; Schuster F; Kranke P; Roewer N; Anetseder M
    Eur J Anaesthesiol; 2011 Apr; 28(4):251-5. PubMed ID: 20827211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic testing for malignant hyperthermia in North America.
    Nelson TE; Rosenberg H; Muldoon SM
    Anesthesiology; 2004 Feb; 100(2):212-4. PubMed ID: 14739790
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of in vitro contracture testing with ryanodine, halothane and caffeine in malignant hyperthermia and other neuromuscular disorders.
    Hopkins PM; Ellis FR; Halsall PJ
    Br J Anaesth; 1993 Apr; 70(4):397-401. PubMed ID: 8499197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations.
    Rueffert H; Olthoff D; Deutrich C; Meinecke CD; Froster UG
    Acta Anaesthesiol Scand; 2002 Jul; 46(6):692-8. PubMed ID: 12059893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B lymphocytes.
    Sei Y; Brandom BW; Bina S; Hosoi E; Gallagher KL; Wyre HW; Pudimat PA; Holman SJ; Venzon DJ; Daly JW; Muldoon S
    Anesthesiology; 2002 Nov; 97(5):1052-8. PubMed ID: 12411786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility.
    Monnier N; Krivosic-Horber R; Payen JF; Kozak-Ribbens G; Nivoche Y; Adnet P; Reyford H; Lunardi J
    Anesthesiology; 2002 Nov; 97(5):1067-74. PubMed ID: 12411788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sevoflurane is less sensitive than halothane for in vitro detection of malignant hyperthermia susceptibility.
    Johannsen S; Klingler W; Schneiderbanger D; Heiderich S; Roewer N; Schuster F
    Acta Anaesthesiol Scand; 2013 Oct; 57(9):1161-6. PubMed ID: 23957432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant hyperthermia susceptibility, an autosomal dominant disorder?
    Fagerlund TH; Islander G; Ranklev Twetman E; Berg K
    Clin Genet; 1997 Jun; 51(6):365-9. PubMed ID: 9237497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the caffeine halothane muscle contracture test with the molecular genetic diagnosis of malignant hyperthermia.
    MacKenzie AE; Allen G; Lahey D; Crossan ML; Nolan K; Mettler G; Worton RG; MacLennan DH; Korneluk R
    Anesthesiology; 1991 Jul; 75(1):4-8. PubMed ID: 2064058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.